Literature DB >> 12226038

Comparison of sputum induction using high-output and low-output ultrasonic nebulizers in normal subjects and patients with COPD.

Martin G Kelly1, Vanessa Brown, S Lorraine Martin, Madeleine Ennis, J Stuart Elborn.   

Abstract

STUDY
OBJECTIVE: s: Induced sputum is used to investigate pulmonary diseases. Low-output ultrasonic nebulizers have become available and have potential advantages over high-output nebulizers. We hypothesized that a low-output nebulizer would give comparable results to a high-output nebulizer, with an acceptable safety profile.
DESIGN: Randomized, crossover study.
SETTING: University teaching hospital. PARTICIPANTS: Ten normal subjects and 10 patients with COPD.
INTERVENTIONS: Participants attended for sputum induction on two occasions in random order using low-output and high-output nebulizers. MEASUREMENTS AND
RESULTS: Lung function and oxygen saturation were measured during sputum induction, and tolerability of the procedure was assessed. Cell counts, interleukin 8, and neutrophil elastase were measured in sputum. Use of the high-output nebulizer resulted in a greater FEV(1) (mean +/- SEM, 0.29 +/- 0.04 L vs 0.21 +/- 0.04 L; p = 0.04) and percentage drop in FEV(1) (25.8 +/- 2.6% vs 19.5 +/- 2.9%, respectively; p = 0.02) compared with the low-output nebulizer in patients with COPD. There was a shorter tolerated nebulization time with the high-output nebulizer compared with the low-output nebulizer: 12.7 +/- 2.0 min vs 16.5 +/- 1.8 min, respectively (p = 0.02). Modified Borg scores were lower with the low-output nebulizer than the high-output nebulizer in normal subjects: median, 0 (interquartile range [IQR], 0 to 1) vs median, 1.5 (IQR, 0 to 2), respectively (p = 0.05). There were no differences in cell counts and soluble markers of inflammation.
CONCLUSIONS: The low-output ultrasonic nebulizer is comparable to high-output nebulizer for cellular and soluble markers of inflammation, results in a smaller reduction in FEV(1), is better tolerated, and is a suitable tool for investigating airway inflammation in patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226038     DOI: 10.1378/chest.122.3.955

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  SPLUNC1 promotes lung innate defense against Mycoplasma pneumoniae infection in mice.

Authors:  Fabienne Gally; Y Peter Di; Sean K Smith; Maisha N Minor; Yang Liu; Donna L Bratton; S Courtney Frasch; Nicole M Michels; Stephanie R Case; Hong Wei Chu
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Neutrophil cell death, activation and bacterial infection in cystic fibrosis.

Authors:  A P Watt; J Courtney; J Moore; M Ennis; J S Elborn
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

3.  Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis.

Authors:  A P Watt; V Brown; J Courtney; M Kelly; L Garske; J S Elborn; M Ennis
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

4.  Dysregulated apoptosis and NFkappaB expression in COPD subjects.

Authors:  Vanessa Brown; J Stuart Elborn; Judy Bradley; Madeleine Ennis
Journal:  Respir Res       Date:  2009-03-18

5.  Sputum analysis in diagnosis and management of obstructive airway diseases.

Authors:  Paige Lacy; Jennifer L Lee; Dilini Vethanayagam
Journal:  Ther Clin Risk Manag       Date:  2005-09       Impact factor: 2.423

6.  Airway inflammation and anti-protease defences rapidly improve during treatment of an acute exacerbation of COPD.

Authors:  Sushil Pant; Eugene H Walters; Anne Griffiths; Richard Wood-Baker; David P Johns; David W Reid
Journal:  Respirology       Date:  2009-05       Impact factor: 6.424

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.